|
Recent Developments |
|
01-JUN-17
Claris Lifesciences (CLL) along with its wholly owned subsidiary Claris Injectables (CIL) has underwent a successful USFDA Pharmacovigilance (PV) audit from May 29 to May 31 with No Observation (i483s).
08-MAY-17
Claris Lifesciences has received an approval for the sale and transfer of the equity shares of Otsuka Pharmaceutical India (formerly knowns as Claris Otsuka) to Otsuka Pharmaceutical Factory, Inc for a consideration of USD 2... More.. |
| Business Profile |
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 30-Jun-2016(6) | 31-Dec-2015(12) | 31-Dec-2014(12) | | Net sales | 1387.20 | 5531.52 | 5925.71 | | Other Income | 248.63 | 512.18 | 680.74 | | Total Income | 1635.83 | 6043.70 | 6606.45 | | Cost of goods sold | 1503.00 | 5765.21 | 4824.56 | | OPBDIT | 132.83 | 278.49 | 1781.89 | | PAT | 71.87 | -57.70 | 1414.68 | | Gross Block | - | - | - | | Equity capital | 545.68 | 545.68 | 545.68 | | EPS (Rs.) | - | - | - | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | - | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 8.1 | 4.6 | 27.0 | | Net margin (% of OI) | 4.4 | -1.0 | 21.4 |
|
|
Detailed Financials
|
|
|
|
|
